A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Inclusion Criteria:

- Subjects and/or parent(s)/legally acceptable representative must be considered willing
and able to sign consent, and complete daily dosing and seizure diaries and complete
all scheduled visits.

- Male and female epilepsy subjects, 1 month to 65 years of age inclusive on the date of
the Screening Visit.

- Diagnosis of epilepsy with seizures classified as simple partial, complex partial, or
partial becoming secondarily generalized, or primary generalized tonic-clonic seizures
according to the International League Against Epilepsy (ILAE 2010) Diagnosis Criteria.

- Partial onset seizure subjects must have had an average of at least 3 seizures per 28
day period in the 3 months prior to screening.

- Currently receiving a stable dose of 1 to 3 antiepileptic drugs (stable within 28 days
prior to screening).

Exclusion Criteria:

- Lennox-Gastaut syndrome, Infantile Spasms, Absence seizures, BECT (Benign Epilepsy
with Centrotemporal Spikes), and Dravet syndrome,

- A current diagnosis of febrile seizures or any febrile seizure within 1 year of
screening.

- Status epilepticus within 1 year prior to visit 1.

- Seizures related to drugs, alcohol, or acute medical illness.

- Progressive structural CNS lesion or a progressive encephalopathy.